Javascript must be enabled to continue!
Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)
View through CrossRef
SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.AimTo investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD.MethodsWe used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015. US‐Fatty Liver Index in absence of secondary causes identified NAFLD. Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.ResultsNAFLD prevalence among 5211 adults (46.2% male; 75.8% white; mean age 53.2 years) was 32.7%. Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.5% vs 64.8%) or highly active PA (≥300 min/week, 39.2% vs 48.5%) compared to adults without NAFLD. Over a median follow‐up of 12.3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered. In the metabolic comorbidities‐adjusted model, adults with NAFLD who reported ≥50% of their total PA as vigorous activity had a 56% reduction in all‐cause mortality risk (HR:0.44, 95%CI: 0.25–0.76) and cancer‐specific mortality risk (HR: 0.21, 0.06–0.66) but not cardiac‐specific mortality (p > 0.05) compared to adults with NAFLD who did not report any LTPA. This association remained significant even among adults with NAFLD who met the recommended minimal PA, among adults with NAFLD who reported any LTPA, and among adults with NAFLD who had metabolic abnormalities and in sensitivity analysis.ConclusionsEngaging in vigorous activity is beneficial for adults with NAFLD ‐ especially those with metabolic abnormalities.
Title: Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)
Description:
SummaryBackgroundMortality benefits of vigorous leisure time physical activity (LTPA) among adults with NAFLD is not known.
AimTo investigate association between LTPA and reduction in all‐cause mortality among adults with NAFLD.
MethodsWe used NHANES (1999–2006) self‐reported PA data for adults (≥40 years) with mortality follow‐up through December 31, 2015.
US‐Fatty Liver Index in absence of secondary causes identified NAFLD.
Moderate and vigorous LTPA were calculated by the 2018 PA Guidelines for Americans.
ResultsNAFLD prevalence among 5211 adults (46.
2% male; 75.
8% white; mean age 53.
2 years) was 32.
7%.
Adults with NAFLD were less likely to report the recommended minimal PA (≥ 150 min/week, 55.
5% vs 64.
8%) or highly active PA (≥300 min/week, 39.
2% vs 48.
5%) compared to adults without NAFLD.
Over a median follow‐up of 12.
3 years, 355 deaths among adults with NAFLD and 510 deaths among adults without NAFLD were registered.
In the metabolic comorbidities‐adjusted model, adults with NAFLD who reported ≥50% of their total PA as vigorous activity had a 56% reduction in all‐cause mortality risk (HR:0.
44, 95%CI: 0.
25–0.
76) and cancer‐specific mortality risk (HR: 0.
21, 0.
06–0.
66) but not cardiac‐specific mortality (p > 0.
05) compared to adults with NAFLD who did not report any LTPA.
This association remained significant even among adults with NAFLD who met the recommended minimal PA, among adults with NAFLD who reported any LTPA, and among adults with NAFLD who had metabolic abnormalities and in sensitivity analysis.
ConclusionsEngaging in vigorous activity is beneficial for adults with NAFLD ‐ especially those with metabolic abnormalities.
Related Results
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
The NAFLD fibrosis score : a prognostic predictor for mortality and liver complications among NAFLD patients
The NAFLD fibrosis score : a prognostic predictor for mortality and liver complications among NAFLD patients
Background: The prognostic indicators for long-term outcomes of non alcoholic fatty liver disease (NAFLD) patients have not been well studied. We aimed to validate the NAFLD Fibros...
Association of Lipid Profile Abnormalities with NAFLD Severity in Patients with Metabolic Syndrome
Association of Lipid Profile Abnormalities with NAFLD Severity in Patients with Metabolic Syndrome
Background: Nonalcoholic fatty liver disease (NAFLD) is becoming a significant global health issue, and it is frequently associated with metabolic conditions, including hypertensio...
Hepatologists’ Awareness and Knowledge of NAFLD and the Familiarity
with Renaming NAFLD to MAFLD
Hepatologists’ Awareness and Knowledge of NAFLD and the Familiarity
with Renaming NAFLD to MAFLD
Background & Aims:
Non-alcoholic fatty liver disease (NAFLD) is an emerging epidemic;
it is a negative diagnosis that depends mainly on the presence of hepatic steatosis with o...
Clinical and diagnostic characteristics of non-alcoholic fatty liver disease among Egyptian children and adolescents with type1 diabetes
Clinical and diagnostic characteristics of non-alcoholic fatty liver disease among Egyptian children and adolescents with type1 diabetes
Abstract
Background
Type 1 diabetes mellitus (T1DM) patients are at an increased risk for non-alcoholic fatty liver disea...
OR25-06 The Effect of Testosterone Replacement Therapy on NAFLD in Elderly Hypogonadal Men
OR25-06 The Effect of Testosterone Replacement Therapy on NAFLD in Elderly Hypogonadal Men
Abstract
Disclosure: H. Lee: None. S. Han: None. R.S. Swerdloff: None. Y. Pak: None. M.J. Budoff: None. C.C. Wang: None.
The Effect of Testosterone Re...

